Drug Approval | March 27, 2024
Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
This product has sales of about US$ 20 million in Europe
Furthering cell therapy ambition across oncology and autoimmune diseases
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Subscribe To Our Newsletter & Stay Updated
